Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hydroxylamine derivatives as a new paradigm in the search of antibacterial agents

  • Miret-Casals, Laia
  • Baelo, Aida
  • Julián, Esther|||0000-0002-6558-3978
  • Astola, Josep
  • Lobo-Ruiz, Ariadna
  • Albericio, Fernando|||0000-0002-8946-0462
  • Torrents, Eduard|||0000-0002-3010-1609
Serious infections caused by bacteria that are resistant to commonly used antibiotics have become a major global healthcare problem in the 21st century. Multidrug-resistant bacteria causing severe infections mainly grow in complex bacterial communities known as biofilms, in which bacterial resistance to antibacterial agents and to the host immune system is strengthened. As drug resistance is becoming a threatening problem, it is necessary to develop new antimicrobial agents with novel mechanisms of action. Here, we designed and synthesized a small library of N -substituted hydroxylamine (N-HA) compounds with antibacterial activity. These compounds, acting as radical scavengers, inhibit the bacterial ribonucleotide reductase (RNR) enzyme. RNR enzyme is essential for bacterial proliferation during infection, as it provides the building blocks for DNA synthesis and repair. We demonstrate the broad antimicrobial effect of several drug candidates against a variety of Gram-positive and Gram-negative bacteria, together with low toxicity toward eukaryotic cells. Furthermore, the most promising compounds can reduce the biomass of an established biofilm on Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. This study settles the starting point to develop new N -hydroxylamine compounds as potential effective antibacterial agents to fight against drug-resistant pathogenic bacteria.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment

  • Bach Griera, Marc|||0000-0001-9845-7225
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Barbosa Perez, Sandra
  • Traserra Call, Sara
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Moya Andérico, Laura|||0000-0001-8471-9853
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Rabanal Prados, Rosa Ma|||0000-0002-9521-791X
  • Torrents, Eduard|||0000-0002-3010-1609
  • Julián, Esther|||0000-0002-6558-3978
Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae - and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae -intravesically-treated BALB/c mice, and intrahemacoelic-infected- Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Differences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BCG Substrains Change Their Outermost Surface as a Function of Growth Media

  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Almiñana-Rapún, Farners
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Torrents, Eduard|||0000-0002-3010-1609
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Julián, Esther|||0000-0002-6558-3978
Mycobacterium bovis bacillus Calmette-Guérin (BCG) efficacy as an immunotherapy tool can be influenced by the genetic background or immune status of the treated population and by the BCG substrain used. BCG comprises several substrains with genetic differences that elicit diverse phenotypic characteristics. Moreover, modifications of phenotypic characteristics can be influenced by culture conditions. However, several culture media formulations are used worldwide to produce BCG. To elucidate the influence of growth conditions on BCG characteristics, five different substrains were grown on two culture media, and the lipidic profile and physico-chemical properties were evaluated. Our results show that each BCG substrain displays a variety of lipidic profiles on the outermost surface depending on the growth conditions. These modifications lead to a breadth of hydrophobicity patterns and a different ability to reduce neutral red dye within the same BCG substrain, suggesting the influence of BCG growth conditions on the interaction between BCG cells and host cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

  • Alcon, Clara
  • Manzano-Muñoz, Albert|||0000-0003-4039-7391
  • Prada, Estela|||0000-0003-4611-1120
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Soriano, Aroa|||0000-0001-9659-1471
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
  • Samitier, Josep|||0000-0002-1140-3679
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Montero, Joan|||0000-0002-9192-4836
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse. Indeed, we found that BH3 mimetics that selectively target anti-apoptotic BCL-xL and MCL-1, synergistically enhance the effect of clinically used chemotherapeutic agents vincristine and doxorubicin in RMS cells. We validated this strategy in vivo using a RMS patient-derived xenograft model and observed a reduction in tumor growth with a tendency to stabilization with the sequential combination of vincristine and the MCL-1 inhibitor S63845. We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845. Our findings validate the use of DBP as a functional assay to predict treatment effectiveness in RMS and provide a rationale for combining BH3 mimetics with chemotherapeutic agents to avoid tumor resistance, improve treatment efficiency, and decrease undesired secondary effects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining microfluidics with machine learning algorithms for RBC classification in rare hereditary hemolytic anemia

  • Rizzuto, Valeria|||0000-0003-4728-6977
  • Mencattini, Arianna
  • Álvarez-González, Begoña
  • Di Giuseppe, Davide
  • Beneitez Pastor, David|||0000-0002-6541-6600
  • Mañú Pereira, María del Mar|||0000-0003-4770-7460
  • Lopez-Martinez, Maria José
  • Samitier, Josep|||0000-0002-1140-3679
Combining microfluidics technology with machine learning represents an innovative approach to conduct massive quantitative cell behavior study and implement smart decision-making systems in support of clinical diagnostics. The spleen plays a key-role in rare hereditary hemolytic anemia (RHHA), being the organ responsible for the premature removal of defective red blood cells (RBCs). The goal is to adapt the physiological spleen filtering strategy for in vitro study and monitoring of blood diseases through RBCs shape analysis. Then, a microfluidic device mimicking the slits of the spleen red pulp area and video data analysis are combined for the characterization of RBCs in RHHA. This microfluidic unit is designed to evaluate RBC deformability by maintaining them fixed in planar orientation, allowing the visual inspection of RBC's capacity to restre their original shape after crossing microconstrictions. Then, two cooperative learning approaches are used for the analysis: the majority voting scheme, in which the most voted label for all the cell images is the class assigned to the entire video; and the maximum sum of scores to decide the maximally scored class to assign. The proposed platform shows the capability to discriminate healthy controls and patients with an average efficiency of 91%, but also to distinguish between RHHA subtypes, with an efficiency of 82%.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

  • Manzano-Muñoz, A.
  • Alcon, Clara
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Seyfried, F.
  • Debatin, K.M.
  • Meyer, L.H.
  • Samitier, J.
  • Montero, J.
Multiple targeted therapies are currently explored for pediatric and young adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new armamentarium of therapies faces an old problem: choosing the right treatment for each patient. The lack of predictive biomarkers is particularly worrying for pediatric patients since it impairs the implementation of new treatments in the clinic. In this study, we used the functional assay dynamic BH3 profiling (DBP) to evaluate two new treatments for BCP-ALL that could improve clinical outcome, especially for relapsed patients. We found that the MEK inhibitor trametinib and the multi-target tyrosine kinase inhibitor sunitinib exquisitely increased apoptotic priming in an NRAS-mutant and in a KMT2A-rearranged cell line presenting a high expression of FLT3, respectively. Following these observations, we sought to study potential adaptations to these treatments. Indeed, we identified with DBP anti-apoptotic changes in the BCL-2 family after treatment, particularly involving MCL-1 - a pro-survival strategy previously observed in adult cancers. To overcome this adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and evaluated its sequential addition to both kinase inhibitors to overcome resistance. We observed that the metronomic combination of both drugs with S63845 was synergistic and showed an increased efficacy compared to single agents. Similar observations were made in BCP-ALL KMT2A-rearranged PDX cells in response to sunitinib, showing an analogous DBP profile to the SEM cell line. These findings demonstrate that rational sequences of targeted agents with BH3 mimetics, now extensively explored in clinical trials, may improve treatment effectiveness by overcoming anti-apoptotic adaptations in BCP-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Ruiz-Rodriguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard|||0000-0002-3010-1609
  • Chiner-Oms, Álvaro|||0000-0002-0463-0101
  • Torres-Puente, Manuela|||0000-0002-8352-180X
  • Comas, I.|||0000-0001-5504-9408
  • Julián, Esther|||0000-0002-6558-3978
  • Coscolla, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384 T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds

  • Martorell Cedres, Lluis|||0000-0001-9348-4531
  • López-Fernández, Alba|||0000-0001-6072-0294
  • García-Lizarribar, Andrea|||0000-0001-5072-2093
  • Sabata, Roger|||0000-0002-4769-4615
  • Galvez-Martin, Patricia|||0000-0001-9724-8560
  • Samitier, Josep|||0000-0002-1140-3679
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Three dimensional (3D) bioprinting is an emerging technology that enables complex spatial modeling of cell-based tissue engineering products, whose therapeutic potential in regenerative medicine is enormous. However, its success largely depends on the definition of a bioprintable zone, which is specific for each combination of cell-loaded hydrogels (or bioinks) and scaffolds, matching the mechanical and biological characteristics of the target tissue to be repaired. Therefore proper adjustment of the bioink formulation requires a compromise between: (i) the maintenance of cellular critical quality attributes (CQA) within a defined range of specifications to cell component, and (ii) the mechanical characteristics of the printed tissue to biofabricate. Herein, we investigated the advantages of using natural hydrogel-based bioinks to preserve the most relevant CQA in bone tissue regeneration applications, particularly focusing on cell viability and osteogenic potential of multipotent mesenchymal stromal cells (MSCs) displaying tripotency in vitro, and a phenotypic profile of 99.9% CD105/CD45, 10.3% HLA-DR, 100.0% CD90, and 99.2% CD73/CD31 expression. Remarkably, hyaluronic acid, fibrin, and gelatin allowed for optimal recovery of viable cells, while preserving MSC's proliferation capacity and osteogenic potency in vitro. This was achieved by providing a 3D structure with a compression module below 8.8 ± 0.5 kPa, given that higher values resulted in cell loss by mechanical stress. Beyond the biocompatibility of naturally occurring polymers, our results highlight the enhanced protection on CQA exerted by bioinks of natural origin (preferably HA, gelatin, and fibrin) on MSC, bone marrow during the 3D bioprinting process, reducing shear stress and offering structural support for proliferation and osteogenic differentiation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood-Brain Barrier in a µphysiological Model

  • Perxés Perich, Marta|||0000-0003-3062-7288
  • Palma-Florez, Sujey|||0000-0002-6806-0056
  • Solé, Clara
  • Goberna-Ferrón, Sara|||0000-0002-3306-3791
  • Samitier, Josep|||0000-0002-1140-3679
  • Gómez-Romero, Pedro|||0000-0002-6208-5340
  • Mir, Mònica|||0000-0002-1490-8373
  • Lagunas, Anna|||0000-0002-0936-3401
Alzheimer's disease is characterized by a combination of several neuropathological hallmarks, such as extracellular aggregates of beta amyloid (Aβ). Numerous alternatives have been studied for inhibiting Aβ aggregation but, at this time, there are no effective treatments available. Here, we developed the tri-component nanohybrid system AuNPs@POM@PEG based on gold nanoparticles (AuNPs) covered with polyoxometalates (POMs) and polyethylene glycol (PEG). In this work, AuNPs@POM@PEG demonstrated the inhibition of the formation of amyloid fibrils, showing a 75% decrease in Aβ aggregation in vitro. As it is a potential candidate for the treatment of Alzheimer's disease, we evaluated the cytotoxicity of AuNPs@POM@PEG and its ability to cross the blood-brain barrier (BBB). We achieved a stable nanosystem that is non-cytotoxic below 2.5 nM to human neurovascular cells. The brain permeability of AuNPs@POM@PEG was analyzed in an in vitro microphysiological model of the BBB (BBB-on-a-chip), containing 3D human neurovascular cell co-cultures and microfluidics. The results show that AuNPs@POM@PEG was able to cross the brain endothelial barrier in the chip and demonstrated that POM does not affect the barrier integrity, giving the green light to further studies into this system as a nanotherapeutic.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

  • Alcon, Clara
  • Martín, Fernando|||0000-0002-3496-9093
  • Prada, Estela|||0000-0003-4611-1120
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Soriano, Aroa|||0000-0001-9659-1471
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
  • Samitier, Josep|||0000-0002-1140-3679
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Montero, Joan|||0000-0002-9192-4836
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due to tumor adaptations. We used dynamic BH3 profiling to identify targeted agents effectiveness and anti-apoptotic adaptations upon targeted treatment in rhabdomyosarcoma. We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. We observed that the MEK1/2 inhibitor trametinib rapidly depleted the pro-apoptotic protein NOXA, thus increasing MCL-1 availability. Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. In conclusion, our findings indicate that the combination of a BH3 mimetic targeting MCL-1 with trametinib improves efficiency on rhabdomyosarcoma by blocking tumor adaptation to treatment.